We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists

News   Apr 13, 2010

 
MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists
 
 
Advertisement
 

RELATED ARTICLES

Wuhan COVID-19 Vaccine Trials Show Early Positive Results, Moving Forward to Phase 3 Testing

News

The adenovirus type-5-vectored COVID-19 vaccine was shown to be safe and induced significant immune responses in the majority of recipients after a single immunization.

READ MORE

Radiation Sickness Could Be Detected in a Single Drop of Blood

News

A new proof-of-concept study reports evidence that a new testing method has the potential to rapidly identify radiation sickness based on biomarkers measured through a single drop of blood.

READ MORE

Therapy for Nonalcoholic Fatty Liver Disease Shows Promise in Preclinical Tests

News

Scientists have discovered a new target and a new therapy for Nonalcoholic Fatty Liver Disease (NAFLD), that has shown promising results in preclinical mouse models.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE